Insight CSB
Comprehensive genomic profiling of solid tumours from a blood sample
Liquid biopsy cancer genetic test
You are all set!
Your call is booked.
We have just sent a calendar invite to you confirming the date and time for your ‘discovery call’. Please check your junk/spam folder if it is not in your inbox. If you do not receive this email, please email info@rarecan.com and we will get back to you as quickly as possible.
What to expect
- How long is the initial call?
Calls are scheduled for 30 minutes.
- What does the call cover?
On the call we’ll help you to:
- Understand genomic profiling and when it might be an option for you.
- Understand what our Insight CSB genomic test is and how it applies to you.
- Understand our other genomic testing options if relevant to you.
- Have the information necessary to make a decision about whether it’s the right time to go ahead with the test.
We will also explain what other support we can offer if you need more help deciding whether an Insight CSB test is the right option for you.
- Who is the call with?
The call will be with one of our Navigators who are knowledgeable about our genomic tests and clinical trials. Our Navigators are not doctors, so this call does not replace speaking to your oncologist or surgeon.
Supported by:
About our tests
- Our liquid biopsy tests work by analysing cell-free DNA (cfDNA) circulating in your blood to identify and characterise tumour-derived fragments (circulating tumour DNA, or ctDNA).
- Our tissue-based tests work by analysing tumour DNA from samples stored by your hospital following biopsy or surgery.
- The tests use Next Generation Sequencing (NGS) on high throughput Illumina platforms to provide a genomic profile of your cancer.
- Our tests are extensively validated, accredited by the American College of Pathologists (CAP) and performed in an ISO 15198 accredited laboratory.
- Analysis and reporting is undertaken as per international guidelines (ACMG/AMP/ASCO/CAP) using a CE-IVD certified mutation database for variant interpretation and reporting.
- The output from the test is a report highlighting genetic variants found, providing information for clinicians on the potential relevance of any variants, and listing out clinical trials that might be treatment options based on the genomic profile of your cancer.
Regulatory information / disclaimer
- RareCan Insight genomic tests are registered with the Medicines and Healthcare products Regulatory Agency (MHRA) as Class 1 in vitro diagnostic medical devices.
- They are intended for use by healthcare professionals for the qualitative identification of specific somatic variants in circulating tumour DNA (ctDNA) extracted from human whole blood or tumour DNA (tDNA) extracted from tumour tissue samples.
- The tests are intended to support clinicians in identifying potential clinical trials for which you may be eligible.
- The sample collection kits are intended for use by qualified phlebotomists and are not intended for patient self-testing or self-sampling.
- Results must be interpreted by a qualified healthcare professional in conjunction with your full clinical history, other diagnostic test results, and relevant clinical guidelines.
- The results are not intended to be used as the sole basis for treatment decisions, and further confirmatory testing may be required.
